



(FW)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Asa Rosenquist et al.

Examiner: Ha, Julie

Serial No.: 10/572,418

Art Unit: 1654

Filed: March 17, 2006

Docket: 19555

For: HCV-NS-3 SERINE PROTEASE
INHIBITORS

Dated: June 17, 2008

Confirmation No.: 7910

Mail Stop: Amendment
Commissioner for Patent
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, applicants have listed on the attached Form PTO-1449 art to be made of record in the above-identified case.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mailstop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 17, 2008

Dated: June 17, 2008




Mark J. Cohen

Applicants respectfully request that the information cited in this Information Disclosure Statement be made of record herein. Consideration of the information is respectfully requested since the art provided may be material to the examination of the present application as defined in 37 CFR §1.56. It should also be understood that the information listed on the attached PTO 1449 form should not be construed as prior art. There are items listed therein which may be relevant to the examination of the present application although not considered prior art, e.g. U.S. Patent Application S/N 10/572,349 filed March 17, 2006 and U.S. Patent Application S/N 10/632,102 filed January 10, 2007.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(b), no statement or fee is required.

Respectfully submitted,


Mark J. Cohen
Registration No. 32,211

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

MJC:htj

01/04
JUN 20 2008
TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
19555

In Re Application Of
Asa Rosenquist, et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/572,418	March 17, 2006	Julie Ha	23389	1654	7910

Title: HCV NS-3 SERINE PROTEASE INHIBITORS

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:


the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

STP
TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
JUN 20 2008 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
19555

In Re Application of:  Ssa Rosenquist, et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/572,418	March 17, 2006	Julie Ha	23389	1654	7910

Title: HCV NS-3 SERINE PROTEASE INHIBITORS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.

Charge the amount of _____
 Credit any overpayment.
 Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.



Signature

Mark J. Cohen, Esq.


Registration No. 32,211

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

June 17, 2008



(Date)

Signature of Person Mailing Correspondence

Mark J. Cohen

Typed or Printed Name of Person Mailing Certificate

Dated: June 17, 2008

cc: MJC:htj

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

JUN 20 2008

Docket No.
19555

In Re Application Of
Asa Rosenquist, et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/572,418	March 17, 2006	Julie Ha	23389	1654	7910

Title: HCV NS-3 SERINE PROTEASE INHIBITORS

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
19555

In Re Application of: **Asa Rosengquist, et al.**

JUN 20 2008

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/572,418	March 17, 2006	Julie Ha	23389	1654	7910

Title: HCV NS-3 SERINE PROTEASE INHIBITORS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

 (Date)

 Signature

 Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

 June 17, 2008

 (Date)

 Signature of Person Mailing Correspondence

 Mark J. Cohen

 Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Mark J. Cohen
 Signature

Dated: **June 17, 2008**

Mark J. Cohen, Esq.
 Registration No. 32,211
 Scully, Scott, Murphy & Presser, P.C.
 400 Garden City Plaza, Suite 300
 Garden City, New York 11530
 (516) 742-4343

cc: **MJC:htj**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Asa Rosenquist et al.

Examiner: Ha, Julie

Serial No.: 10/572,418

Art Unit: 1654

Filed: March 17, 2006

Docket: 19555

For: HCV-NS-3 SERINE PROTEASE
INHIBITORS

Dated: June 17, 2008

Confirmation No.: 7910

Mail Stop: Amendment
Commissioner for Patent
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, applicants have listed on the attached Form PTO-1449 art to be made of record in the above-identified case.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mailstop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 17, 2008


Dated: June 17, 2008



Mark J. Cohen

Applicants respectfully request that the information cited in this Information Disclosure Statement be made of record herein. Consideration of the information is respectfully requested since the art provided may be material to the examination of the present application as defined in 37 CFR §1.56. It should also be understood that the information listed on the attached PTO 1449 form should not be construed as prior art. There are items listed therein which may be relevant to the examination of the present application although not considered prior art, e.g. U.S. Patent Application S/N 10/572,349 filed March 17, 2006 and U.S. Patent Application S/N 10/632,102 filed January 10, 2007.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(b), no statement or fee is required.

Respectfully submitted,

Mark J. Cohen
Registration No. 32,211

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

MJC:htj

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
19555

In Re Application Of: Asa Rosenquist, et al.

14933
JUN 20 2008

Examiner

Julie Ha

Customer No.

23389

Group Art Unit

1654

Confirmation No.

7910

Title: HCV NS-3 SERINE PROTEASE INHIBITORS

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
19555

In Re Application of: Asa Rosenquist, et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/572,418	March 17, 2006	Julie Ha	23389	1654	7910

Title: HCV NS-3 SERINE PROTEASE INHIBITORS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.

- Charge the amount of _____
- Credit any overpayment.
- Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

June 17, 2008


(Date)

Signature of Person Mailing Correspondence

Mark J. Cohen

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Mark J. Cohen, Esq.
Registration No. 32,211
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

Dated: June 17, 2008

cc: MJC:htj

PATENT OFFICE DATE STAMP WILL ACKNOWLEDGE RECEIPT OF:

1. Response
2. Transmittal of Information Disclosure Statement (in duplicate)
3. Information Disclosure Statement
4. PTO-1449 with References 1-34
5. Certificate of Mailing dated June 17, 2008



Applicant: Asa Rosenquist, et al.
Serial No.: 10/572,418
Filed: January 22, 2007
For: HCV NS-3 SERINE PROTEASE INHIBITORS
Docket: 19555
Date: June 17, 2008
MJC:htj